Category: Include on Menu
-
Silexion Therapeutics Initiates Phase 2/3 Trial of SIL204 in Pancreatic Cancer
The activation of the first clinical site marks the transition of Silexion’s lead RNAi therapy into active Phase 2/3 testing for locally advanced pancreatic cancer. Key Investor Takeaways Why SLXN Stock Is in Focus Silexion Therapeutics (NASDAQ:SLXN) announced the initiation of its Phase 2/3 clinical trial for SIL204 after activating the first study site at…
-
Bandwidth Reports Record Second-Quarter Results and Raises Full-Year 2026 Outlook
Strong demand for AI-enabled communications and enterprise customer wins drove record revenue and adjusted EBITDA, prompting Bandwidth to increase its full-year guidance. Key Investor Takeaways Why BAND Stock Is in Focus Bandwidth (NASDAQ:BAND) delivered record quarterly revenue of $220 million, a 22% increase from the prior year, while adjusted EBITDA rose 27% to $28 million,…
-
Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Financing to Advance BTK Inhibitor Pipeline
The acquisition transforms Processa’s pipeline with the addition of clinical-stage BTK inhibitor VT-7208, while a concurrent $200 million private placement is expected to fund development into 2029. Key Investor Takeaways Why PRCT Stock Is in Focus Processa Pharmaceuticals (NASDAQ:PRCT) announced the acquisition of clinical-stage biotechnology company Vidya Therapeutics in a stock-for-stock transaction, adding its lead…
-
Blackbaud Reports Second-Quarter Results and Reaffirms 2026 Outlook
The software provider expects to finish fiscal 2026 in the upper half of its guidance ranges after delivering steady revenue growth, stronger cash flow, and continued AI investment. Key Investor Takeaways Why BLKB Stock Is in Focus Blackbaud (NASDAQ:BLKB) reported second-quarter 2026 revenue of $290.6 million, a 3.0% increase from the prior year, as recurring…
-
Global Mofy Reports 49.4% Revenue Growth as AI Digital Asset Business Expands
Strong top-line growth was driven by virtual technology services and a new AI digital asset sales business, although higher investment and asset impairment resulted in a GAAP net loss. Key Investor Takeaways Why GMM Stock Is in Focus Global Mofy (NASDAQ:GMM) reported first-half fiscal 2026 revenue of $39.9 million, up 49.4% from $26.7 million a…
-
SciSparc Advances Quantum Clinical Data Analytics as NeuroThera Validates Proprietary Computing Platform
NeuroThera completed internal validation of a quantum-enabled workflow designed to enhance clinical trial data analysis, supporting SciSparc’s broader healthcare technology strategy. Key Investor Takeaways Why SPRC Stock Is in Focus SciSparc (NASDAQ:SPRC) announced that its majority-owned subsidiary, NeuroThera Labs, has completed internal validation of a proprietary quantum computing workflow designed for clinical trial data analysis.…
-
Nocera Advances AI Infrastructure Strategy with QMAX Technology Acquisition
The deal gives Nocera access to authorized Micron/Crucial memory distribution channels, supporting its planned expansion into AI infrastructure and data centers. Key Investor Takeaways Why NCRA Stock Is in Focus Nocera (NASDAQ:NCRA) announced it has acquired a controlling 30% interest in Taiwan-based QMAX Technology through a variable interest entity (VIE) structure, issuing 300,000 restricted common…
-
Wingstop Shares Rise as Earnings Beat Offsets Revenue Miss
Wingstop Inc. (NASDAQ:WING) reported second-quarter results that exceeded Wall Street’s earnings expectations, although revenue came in below forecasts. Investors responded positively to the stronger profitability, sending the restaurant chain’s shares about 4.5% higher following the results. Adjusted earnings were $1.18 per share, comfortably ahead of analysts’ consensus estimate of $1.03. Revenue increased 6.4% year over…
-
Amphenol Beats Second-Quarter Forecasts as AI Demand Fuels Growth and Outlook Improves
Amphenol Corporation (NYSE:APH) reported stronger-than-expected second-quarter results and issued an upbeat third-quarter outlook, driven by robust demand for AI-related data communications products and contributions from recent acquisitions. The company’s shares rose around 7% in premarket trading following the announcement. The connector manufacturer posted adjusted earnings of $1.35 per share, comfortably ahead of Wall Street’s consensus…
-
Flex Beats First-Quarter Expectations and Raises Full-Year Outlook Despite Share Decline
Flex Ltd. (NASDAQ:FLEX) reported first-quarter results that surpassed Wall Street expectations and lifted its full-year financial outlook, although the manufacturing services company’s shares fell more than 5% in premarket trading following the announcement. The company posted adjusted earnings of $1.00 per share, comfortably ahead of analysts’ consensus estimate of $0.90. Revenue climbed 21% year over…